A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment
Basurte-Villamor, Ignacio (Clínica López Ibor)
Vega, Pablo (Madrid Salud)
Roncero, Carlos (Universidad de Salamanca)
Martínez-Raga, José (Hospital Universitari Doctor Peset (València))
Grau-López, Lara (Hospital Universitari Vall d'Hebron)
Aguilar, Lourdes (Universidad de Salamanca)
Torrens, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Szerman, Nestor (Hospital General Universitario Gregorio Marañón)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). The objective of the study was to describe the effectiveness of vortioxetine in clinical practice and determine its effect on affective symptoms, cognitive function, quality of life, and substance use in patients with MDD and SUD. Post-authorization, retrospective, multicenter, descriptive, and observational study in 80 patients with MDD and SUD receiving a maintenance treatment with vortioxetine for six months between January 2017 and April 2021. Compared with baseline, scores significantly decreased after 3 and 6 months of treatment in the Montgomery-Åsberg Depression Rating Scale total (from 28. 9 to 17. 7 and 12. 0), and global functional impairment of the Sheehan Disability Inventory (from 26. 3 to 19. 1 and 16. 7). The number of correct answers in the symbol digit modalities test significantly improved during vortioxetine treatment (from 40. 4 to 43. 8 and 48. 4). Regarding the clinical global impression scale, the score for disease severity significantly decreased from 3. 8 to 3. 0 and 2. 4. Compared with baseline, there was a significant reduction in consumption of practically all substances, especially of alcohol, cannabis, and cocaine. Vortioxetine was effective in clinical practice for alleviating depressive symptoms and functional impairment, and in improving cognitive and executive functions and disease severity in patients with MDD and SUD. Moreover, the treatment with vortioxetine favored a reduction in substance use and the severity of the SUDs.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Dual disorder ; Major depressive disorder ; Major dual depressive disorder ; Real-world evidence ; Substance use disorder ; Vortioxetine
Publicat a:	Neuropsychiatric Disease and Treatment, Vol. 18 (may 2022) , p. 965-976, ISSN 1178-2021

DOI: 10.2147/NDT.S358782
PMID: 35547266

12 p, 1.7 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats